The prognostic role of pan‐immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium‐177 ( 177 Lu)‐PSMA‐617
The Prostate · 2025
DOI: 10.1002/pros.24804 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Satı Coskun Yazgan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Dipeptides, Inflammation. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Background
Pan‐immune inflammation value (PIV) is a newly defined biomarker that includes whole cellular components that are indicators of systemic inflammation in complete blood count (CBC), easily accessible and has the potential to reflect both the body's immune response and systemic inflammation status. This study evaluated the pretreatment PIV for its prognostic impact on overall survival (OS) in patients with metastatic castration‐resistant prostate cancer (mCRPC) treated with Lutetium‐177 ( 177 Lu)‐PSMA‐617.
Methods
The PIV was based on the earliest CBC obtained within 1 month before treatment initiation. Patients were categorized into low and high PIV groups based on the median pretreatment PIV, and the relationship between OS and PIV groups was assessed by multivariable analysis.
Results
A total of 43 patients with mCRPC treated with ( 177 Lu)‐PSMA‐617 were included. The median OS was longer in the low PIV group (15.1 months [95% confidence interval [CI] 10.6–19.5]) than in the high PIV group (4.2 months [95% CI 1.7–6.6]) ( p < 0.001). In multivariable analysis, high PIV (hazard ratio [HR]: 4.3, 95% CI 1.194–15.93, p = 0.026) and high Eastern Cooperative Oncology Group performance score (HR: 7.05, 95% CI 1.48–33.46, p = 0.014) were associated with shorter OS.
Conclusion
This study showed that pretreatment PIV might be a prognostic factor in patients with mCRPC treated with ( 177 Lu)‐PSMA‐617.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey.
- Cancer Research Institute, Ankara University, Ankara, Turkey.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Nuclear Medicine, Faculty of Medicine, Ankara University, Ankara, Turkey.
ORCID-Profile: Yuksel Urun
Zitieren
APA
Yazgan, S. C., Yekeduz, E., Araz, M., Bolek, H., Kucuk, N. O., & Urun, Y. (2025). The prognostic role of pan‐immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium‐177 ( 177 Lu)‐PSMA‐617. The Prostate. https://doi.org/10.1002/pros.24804
Vancouver
Yazgan SC, Yekeduz E, Araz M, Bolek H, Kucuk NO, Urun Y. The prognostic role of pan‐immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium‐177 ( 177 Lu)‐PSMA‐617. The Prostate. 2025. doi:10.1002/pros.24804
BibTeX
@article{Yazgan2025,
author = {Yazgan, Satı Coskun and Yekeduz, Emre and Araz, Mine and Bolek, Hatice and Kucuk, N Ozlem and Urun, Yuksel},
title = {The prognostic role of pan‐immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium‐177 ( 177 Lu)‐PSMA‐617},
journal = {The Prostate},
year = {2025},
doi = {10.1002/pros.24804}
}
EUVIMED